Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Arizona: - Banner University Medical Center - Tucson — Tucson, Arizona
- University of Arizona Cancer Center-North Campus — Tucson, Arizona
Phase 3 Recruiting NIH
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Arizona: - Banner Children's at Desert — Mesa, Arizona
- Phoenix Childrens Hospital — Phoenix, Arizona
Phase 3 Recruiting Network
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT03550391
Sites in Arizona: - University of Arizona Cancer Center-Orange Grove Campus — Tucson, Arizona
- University of Arizona Cancer Center-North Campus — Tucson, Arizona
Phase 3 Recruiting Industry
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05580562
Sites in Arizona: - Banner MD Anderson Cancer Center — Phoenix, Arizona
- Barrow Neurological Institute — Phoenix, Arizona
- Phoenix Childrens Hospital — Phoenix, Arizona
- Mayo Clinic Arizona — Phoenix, Arizona
Phase 3 Recruiting Academic/Other
The goal of this Phase 3 clinical trial is to compare the efficacy of niraparib versus temozolomide (TMZ) in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma multiforme (GBM). The main question it aims to answer is: …
Sponsor: Ivy Brain Tumor Center
NCT ID: NCT06388733
Sites in Arizona: - Ivy Brain Tumor Center — Phoenix, Arizona
Phase 3 Recruiting Industry
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together…
Sponsor: NovoCure GmbH
NCT ID: NCT06556563
Sites in Arizona: - Mayo Clinic Hospital — Phoenix, Arizona
Phase 3 Recruiting Industry
The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also imper…
Sponsor: CarThera
NCT ID: NCT05902169
Sites in Arizona: - Mayo Clinic Arizona — Phoenix, Arizona
Phase 3 Recruiting Industry
This is a Phase 3 prospective, randomized, superiority, open-label, multi-site study. The overview of this study is as follows: * A Screening/Baseline Period of 21 days. During this time, patients will be randomized into a 1:2 allocation o…
Sponsor: GT Medical Technologies, Inc.
NCT ID: NCT07195591
Sites in Arizona: - HonorHealth Scottsdale Osborn Medical Center — Scottsdale, Arizona
Phase 3 Recruiting Academic/Other
This phase III trial studies the side effects and how well stereotactic radiosurgery (SRS) works before or after surgery in patients with tumors that has spread to the brain or that can be removed by surgery. Stereotactic radiosurgery is a…
Sponsor: Mayo Clinic
NCT ID: NCT03750227
Sites in Arizona: - Mayo Clinic in Arizona — Scottsdale, Arizona
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05099003
Sites in Arizona: - Banner Children's at Desert — Mesa, Arizona
- Phoenix Childrens Hospital — Phoenix, Arizona
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Arizona: - Phoenix Childrens Hospital — Phoenix, Arizona
Phase 1, Phase 2 Recruiting Industry
This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the secon…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06810544
Sites in Arizona: - Mayo Clinic Scottsdale — Scottsdale, Arizona
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Arizona: - Banner Health- MD Anderson Cancer Center — Gilbert, Arizona
Phase 2 Recruiting Academic/Other
This phase II trial compares the effect of single fraction stereotactic radiosurgery to fractionated stereotactic radiosurgery for the treatment of patients with cancer that has spread to the brain (metastatic brain disease). Stereotactic …
Sponsor: Mayo Clinic
NCT ID: NCT05222620
Sites in Arizona: - Mayo Clinic in Arizona — Scottsdale, Arizona
Phase 1, Phase 2 Recruiting Industry
The purpose of the study is to determine the recommended dose and further understand the safety of MT-125 in participants who have been diagnosed with glioblastoma, a primary brain tumor, when administered in combination with your standard…
Sponsor: Myosin Therapeutics Inc.
NCT ID: NCT07185880
Sites in Arizona: - Mayo Clinic Hospital — Phoenix, Arizona
Phase 2 Recruiting Academic/Other
This phase II trial tests how well retifanlimab with bevacizumab and hypofractionated radiotherapy, compared to bevacizumab and hypofractionated radiotherapy alone, works in treating patients with glioblastoma that has come back after a pe…
Sponsor: Academic and Community Cancer Research United
NCT ID: NCT06160206
Sites in Arizona: - Mayo Clinic in Arizona — Scottsdale, Arizona
Phase 2 Recruiting Academic/Other
This phase II trial studies the clinical outcomes of hypofractionated radiation therapy in patients with diffuse midline gliomas. This study aims to change the way radiation is delivered, from giving 6 weeks of radiation all at once to giv…
Sponsor: Mayo Clinic
NCT ID: NCT05077735
Sites in Arizona: - Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Phase 2 Recruiting Academic/Other
The goal of this diagnostic intervention clinical trial is to compare 18F-Fluciclovine uptake within brain lesions over 60 minutes compared with standard of care positive histology confirmation or confirmation MRI images. The main question…
Sponsor: University of Arizona
NCT ID: NCT06055790
Sites in Arizona: - Arizona Cancer Center at UMC North/University Medical Center — Tucson, Arizona
Phase 1 Recruiting Industry
This is a phase I, open-Label, single/multiple dose, dose-escalation study to evaluate the safety, tolerability and antitumor activity of anti-B7-H3 CAR-T cell injection (TX103) in subjects with recurrent or progressive Grade 4 Glioma.The …
Sponsor: Tcelltech Inc.
NCT ID: NCT06482905
Sites in Arizona: - Mayo Clinic in Arizona — Phoenix, Arizona
EARLY Phase 1 Recruiting Academic/Other
This study will administer the investigational drug, BDTX-1535 to eligible patients with recurrent high-grade glioma (HGG) and newly-diagnosed glioblastoma (nGBM). BDTX-1535 was designed to block a growth signal important to some cancers. …
Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
NCT ID: NCT06072586
Sites in Arizona: - Chandler Regional Medical Center — Chandler, Arizona
- St. Joseph's Hospital and Medical Center — Phoenix, Arizona
EARLY Phase 1 Recruiting Academic/Other
This is an open-label, multi-center, Phase 0/1 dose-escalation trial designed to enroll up to 9 total recurrent glioblastoma (rGBM) participants with confirmed MTAP loss/deletion in their archival or pretreatment biopsy tissue, who are sch…
Sponsor: Nader Sanai
NCT ID: NCT06883747
Sites in Arizona: - St. Joseph's Hospital and Medical Center — Phoenix, Arizona
EARLY Phase 1 Recruiting Academic/Other
This is an open-label, multi-center, Phase 0/2 trial designed to enroll up to 78 total participants with suspected newly diagnosed glioblastoma (nGBM) who are scheduled for surgical resection to accrue at least 14 participants in Arm A and…
Sponsor: Nader Sanai
NCT ID: NCT07485049
Sites in Arizona: - St. Joseph's Hospital and Medical Center — Phoenix, Arizona
EARLY Phase 1 Recruiting Academic/Other
This will be an open-label Phase 0/1 study that will enroll approximately 15 participants, 9 participants with recurrent WHO Grade 4 glioma (rGBM) and 6 participants with brain metastases, who will receive the investigational drug risvutat…
Sponsor: Nader Sanai
NCT ID: NCT07268053
Sites in Arizona: - St. Joseph's Hospital and Medical Center — Phoenix, Arizona
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Arizona: - Massive Bio SYNERGY-AI site — Scottsdale, Arizona
Phase 4 Recruiting Industry
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the r…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT03340506
Sites in Arizona: - Honor Health Research Institute — Scottsdale, Arizona
- Honor Health Research Institute — Scottsdale, Arizona